ClinicalTrials.gov record
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
ClinicalTrials.gov ID: NCT02713204
Public ClinicalTrials.gov record NCT02713204. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Study identification
- NCT ID
- NCT02713204
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Enrollment
- 365 participants
Conditions and interventions
Conditions
Interventions
- REGN910-3 Drug
- Intravitreal Aflibercept Injection (IAI) Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 30, 2016
- Primary completion
- Oct 2, 2017
- Completion
- Oct 2, 2017
- Last update posted
- May 6, 2019
2016 – 2017
United States locations
- U.S. sites
- 87
- U.S. states
- 31
- U.S. cities
- 77
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Investigational Site | Mobile | Alabama | — | — |
| Regeneron Investigational Site 1 | Phoenix | Arizona | — | — |
| Regeneron Investigational Site 2 | Phoenix | Arizona | — | — |
| Regeneron Investigational Site 3 | Phoenix | Arizona | — | — |
| Regeneron Investigational Site 1 | Tucson | Arizona | — | — |
| Regeneron Investigational Site 2 | Tucson | Arizona | — | — |
| Regeneron Investigational Site | Arcadia | California | — | — |
| Regeneron Investigational Site | Bakersfield | California | — | — |
| Regeneron Investigational Site | Beverly Hills | California | — | — |
| Regeneron Investigational Site | Encino | California | — | — |
| Regeneron Investigational Site 1 | Los Angeles | California | — | — |
| Regeneron Investigational Site 2 | Los Angeles | California | — | — |
| Regeneron Investigational Site | Mountain View | California | — | — |
| Regeneron Investigational Site | Oceanside | California | — | — |
| Regeneron Investigational Site 1 | Palm Desert | California | — | — |
| Regeneron Investigational Site 2 | Palm Desert | California | — | — |
| Regeneron Investigational Site | Palo Alto | California | — | — |
| Regeneron Investigational Site | Poway | California | — | — |
| Regeneron Investigational Site | Redlands | California | — | — |
| Regeneron Investigational Site | Sacramento | California | — | — |
| Regeneron Investigational Site | Santa Maria | California | — | — |
| Regeneron Investigational Site | New London | Connecticut | — | — |
| Regeneron Investigational Site | Altamonte Springs | Florida | — | — |
| Regeneron Investigational Site | Fort Lauderdale | Florida | — | — |
| Regeneron Investigational Site | Lakeland | Florida | — | — |
| Regeneron Investigational Site | Largo | Florida | — | — |
| Regeneron Investigational Site | Miami | Florida | — | — |
| Regeneron Investigational Site | Naples | Florida | — | — |
| Regeneron Investigational Site | Palm Beach | Florida | — | — |
| Regeneron Investigational Site | Tallahassee | Florida | — | — |
| Regeneron Investigational Site | Winter Haven | Florida | — | — |
| Regeneron Investigational Site | Augusta | Georgia | — | — |
| Regeneron Investigational Site | Decatur | Georgia | — | — |
| Regeneron Investigational Site | ‘Aiea | Hawaii | — | — |
| Regeneron Investigational Site 1 | Chicago | Illinois | — | — |
| Regeneron Investigational Site 2 | Chicago | Illinois | — | — |
| Regeneron Investigational Site | Lemont | Illinois | — | — |
| Regeneron Investigational Site | Oak Forest | Illinois | — | — |
| Regeneron Investigational Site | Oak Park | Illinois | — | — |
| Regeneron Investigational Site | Urbana | Illinois | — | — |
| Regeneron Investigational Site | New Albany | Indiana | — | — |
| Regeneron Investigational Site | Des Moines | Iowa | — | — |
| Regeneron Investigational Site | Metairie | Louisiana | — | — |
| Regeneron Investigational Site 1 | Baltimore | Maryland | — | — |
| Regeneron Investigational Site 2 | Baltimore | Maryland | — | — |
| Regeneron Investigational Site | Chevy Chase | Maryland | — | — |
| Regeneron Investigational Site 1 | Boston | Massachusetts | — | — |
| Regeneron Investigational Site 2 | Boston | Massachusetts | — | — |
| Regeneron Investigational Site | Jackson | Michigan | — | — |
| Regeneron Investigational Site | Minneapolis | Minnesota | — | — |
| Regeneron Investigational Site | St Louis | Missouri | — | — |
| Regeneron Investigational Site | Las Vegas | Nevada | — | — |
| Regeneron Investigational Site | Portsmouth | New Hampshire | — | — |
| Regeneron Investigational Site | Edison | New Jersey | — | — |
| Regeneron Investigational Site | Teaneck | New Jersey | — | — |
| Regeneron Investigational Site | Albuquerque | New Mexico | — | — |
| Regeneron Investigational Site | Albany | New York | — | — |
| Regeneron Investigational Site | Bloomfield | New York | — | — |
| Regeneron Investigational Site | Great Neck | New York | — | — |
| Regeneron Investigational Site | Hauppauge | New York | — | — |
| Regeneron Investigational Site | Rochester | New York | — | — |
| Regeneron Investigational Site | Syracuse | New York | — | — |
| Regeneron Investigational Site | Asheville | North Carolina | — | — |
| Regeneron Investigational Site | Charlotte | North Carolina | — | — |
| Regeneron Investigational Site | Durham | North Carolina | — | — |
| Regeneron Investigational Site | Cleveland | Ohio | — | — |
| Regeneron Investigational Site | Dublin | Ohio | — | — |
| Regeneron Investigational Site | Portland | Oregon | — | — |
| Regeneron Investigational Site | Camp Hill | Pennsylvania | — | — |
| Regeneron Investigational Site | Huntingdon | Pennsylvania | — | — |
| Regeneron Investigational Site | Ladson | South Carolina | — | — |
| Regeneron Investigational Site | Rapid City | South Dakota | — | — |
| Regeneron Investigational Site | Germantown | Tennessee | — | — |
| Regeneron Investigational Site | Knoxville | Tennessee | — | — |
| Regeneron Investigational Site | Nashville | Tennessee | — | — |
| Regeneron Investigational Site | Abilene | Texas | — | — |
| Regeneron Investigational Site 1 | Austin | Texas | — | — |
| Regeneron Investigational Site 2 | Austin | Texas | — | — |
| Regeneron Investigational Site | Dallas | Texas | — | — |
| Regeneron Investigational Site 1 | Fort Worth | Texas | — | — |
| Regeneron Investigational Site 2 | Fort Worth | Texas | — | — |
| Regeneron Investigational Site | Harlingen | Texas | — | — |
| Regeneron Investigational Site | Houston | Texas | — | — |
| Regeneron Investigational Site | The Woodlands | Texas | — | — |
| Regeneron Investigational Site | Willow Park | Texas | — | — |
| Regeneron Investigational Site | Salt Lake City | Utah | — | — |
| Regeneron Investigational Site | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02713204, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2019 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02713204 live on ClinicalTrials.gov.